1. Home
  2. LEGN vs LSCC Comparison

LEGN vs LSCC Comparison

Compare LEGN & LSCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • LSCC
  • Stock Information
  • Founded
  • LEGN 2014
  • LSCC 1983
  • Country
  • LEGN United States
  • LSCC United States
  • Employees
  • LEGN N/A
  • LSCC N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • LSCC Semiconductors
  • Sector
  • LEGN Health Care
  • LSCC Technology
  • Exchange
  • LEGN Nasdaq
  • LSCC Nasdaq
  • Market Cap
  • LEGN 7.0B
  • LSCC 6.8B
  • IPO Year
  • LEGN 2020
  • LSCC 1989
  • Fundamental
  • Price
  • LEGN $28.91
  • LSCC $46.64
  • Analyst Decision
  • LEGN Strong Buy
  • LSCC Strong Buy
  • Analyst Count
  • LEGN 13
  • LSCC 12
  • Target Price
  • LEGN $75.67
  • LSCC $63.58
  • AVG Volume (30 Days)
  • LEGN 1.7M
  • LSCC 2.9M
  • Earning Date
  • LEGN 05-13-2025
  • LSCC 05-05-2025
  • Dividend Yield
  • LEGN N/A
  • LSCC N/A
  • EPS Growth
  • LEGN N/A
  • LSCC N/A
  • EPS
  • LEGN N/A
  • LSCC 0.37
  • Revenue
  • LEGN $728,303,000.00
  • LSCC $488,736,000.00
  • Revenue This Year
  • LEGN $64.21
  • LSCC $3.39
  • Revenue Next Year
  • LEGN $53.69
  • LSCC $18.55
  • P/E Ratio
  • LEGN N/A
  • LSCC $125.99
  • Revenue Growth
  • LEGN 112.46
  • LSCC N/A
  • 52 Week Low
  • LEGN $27.34
  • LSCC $34.69
  • 52 Week High
  • LEGN $60.87
  • LSCC $78.29
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 39.95
  • LSCC 42.58
  • Support Level
  • LEGN $28.14
  • LSCC $46.41
  • Resistance Level
  • LEGN $31.12
  • LSCC $57.23
  • Average True Range (ATR)
  • LEGN 1.87
  • LSCC 2.26
  • MACD
  • LEGN -0.16
  • LSCC -0.51
  • Stochastic Oscillator
  • LEGN 25.95
  • LSCC 12.19

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About LSCC Lattice Semiconductor Corporation

Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.

Share on Social Networks: